Corticotropin releasing factor type 1 receptor antagonist: a promising therapy for 21-hydroxylase deficiency
10.3760/cma.j.cn101070-20211207-01438
- VernacularTitle:促肾上腺皮质激素释放因子1型受体拮抗剂：21－羟化酶缺陷症治疗新曙光
- Author:
Xiaoxiao LIU
1
;
Shifeng MA
;
Cong ZHANG
;
Yue ZHAO
;
Siqi CHENG
;
Haiyan JIANG
;
Sihan SHENG
;
Rongxiu ZHENG
Author Information
1. 天津医科大学总医院儿科，天津 300052
- Keywords:
21-hydroxylase deficiency;
Corticotropin releasing factor type 1 receptor;
Antagonist
- From:
Chinese Journal of Applied Clinical Pediatrics
2023;38(4):313-317
- CountryChina
- Language:Chinese
-
Abstract:
21-hydroxylase deficiency(21-OHD) is mainly characterized by cortisol deficiency with or without aldosterone deficiency and hyperandrogenemia.The disease requires lifelong exogenous glucocorticoid/salt supplementation.Excessive doses of exogenous glucocorticoids are often needed to control hyperandrogenemia, but the effect is not satisfactory.Corticotropin releasing factor (CRF) type 1 receptor antagonist can directly block the production of adrenocorticotropin, inhibit the generation of adrenogenic androgen, reduce the dose of glucocorticoid therapy, and thus lower the incidence of adverse reactions.In this article, the current research progress on 21-OHD therapy and CRF1 receptor antagonist was reviewed.
